CeriBell (CBLL -22.88%), the neurotechnology company specializing in rapid electroencephalography (EEG) and artificial intelligence for seizure detection, announced its results for Q2 2025 on August 5, 2025. The company’s revenue (GAAP) reached $21.2 million, up from $15.3 million in Q2 2024, outpacing the analyst consensus of $20.45 million (GAAP). Earnings per share (EPS, GAAP) were $(0.38), also better than the expected $(0.40) (GAAP). Despite significant top-line gains and a gross margin increase to 88% ...

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter ...

SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time. Event: Canac ...

Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Financial Results Announcement - CeriBell will release its financial results for the second quarter of 2025 after the close of trading on August 5, 2025 [1] - A conference call to discuss the financial results will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Investor Information - Investors can listen to the conference call by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using access code 7468193 [2] - A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website [2]

Core Viewpoint - Ceribell, Inc. has filed complaints against Natus Medical Incorporated for patent infringement related to point-of-care EEG technology, seeking an investigation and exclusion order from the USITC to prevent the importation of infringing products [1][2]. Company Overview - Ceribell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions, having developed a novel point-of-care EEG platform [5][6]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions, and is FDA-cleared for indicating suspected seizure activity [5]. Legal Actions - Ceribell has filed a complaint with the U.S. International Trade Commission and the U.S. District Court in Delaware, alleging that Natus infringes on six of its patents related to EEG headband and electrode design [1][2]. - The company emphasizes its commitment to fair competition and the protection of its intellectual property to continue delivering innovative products [3].

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA-cleared for detecting suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the William Blair 45 Annual Growth Stock Conference [1] - The presentation is scheduled for Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time [2] - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2]

Core Insights - CeriBell, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $20.5 million, a 42% increase from $14.4 million in Q1 2024, driven by new account adoption and expansion within existing accounts [4][11] - The company is optimistic about continued growth in 2025, focusing on physician education and product development, including the introduction of a pediatric Clarity algorithm [3][8] Financial Performance - Total revenue for Q1 2025 was $20.5 million, up 42% from $14.4 million in Q1 2024, with product revenue at $15.6 million (41% increase) and subscription revenue at $4.9 million (45% increase) [4][15] - Gross profit for Q1 2025 was $18.0 million, with a gross margin of 88%, compared to $12.3 million and 86% in Q1 2024 [5][11] - Operating expenses increased by 55% to $32.2 million in Q1 2025, primarily due to investments in the commercial organization and increased headcount [6][11] - The net loss for Q1 2025 was $12.8 million, or $0.36 per share, compared to a net loss of $8.5 million, or $1.56 per share, in Q1 2024 [7][11] Future Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, indicating a growth of approximately 27% to 33% over the previous year [8] - The company ended Q1 2025 with 558 total active accounts and received FDA clearance for the expansion of its Clarity algorithm, marking a significant milestone [11][11] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through its innovative EEG platform [13]

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. Event ...

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of p ...